Cargando…
Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
Alemtuzumab, an anti-CD52 monoclonal antibody, is effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Common adverse effects include the development of autoimmune diseases, and Graves’ disease is one of the most frequent presentations. We report here a case of alemtuzumab-in...
Autores principales: | Alamo, Angela, Condorelli, Rosita A, La Vignera, Sandro, Calogero, Aldo E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458661/ https://www.ncbi.nlm.nih.gov/pubmed/30968726 http://dx.doi.org/10.1177/2058738419843690 |
Ejemplares similares
-
Evaluation of seminal fluid leukocyte subpopulations in patients with varicocele
por: Mongioì, Laura Maria, et al.
Publicado: (2020) -
Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021) -
SARS-CoV-2: the endocrinological protective clinical model derived from patients with prostate cancer
por: La Vignera, Sandro, et al.
Publicado: (2020) -
Thyroid Hormones and Spermatozoa: In Vitro Effects on Sperm Mitochondria, Viability and DNA Integrity
por: Condorelli, Rosita A., et al.
Publicado: (2019) -
Thyroid Prostate Axis. Does It Really Exist?
por: La Vignera, Sandro, et al.
Publicado: (2019)